{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:20:40Z","timestamp":1787242840857,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011041","name":"Asahi Group Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011041","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with infectious diseases, disseminated intravascular coagulation (DIC) is often diagnosed without the fibrinogen value. The relationship between hypofibrinogenemia and outcomes of DIC in infectious diseases has thus remained unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 3204 patients who received with thrombomodulin alfa (TM-\u03b1) for DIC and suspected DIC. Hypofibrinogenemia was defined by a fibrinogen level\u2009&lt;\u20091.5\u2009g\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hypofibrinogenemia was observed in 10.3% of patients with infectious diseases. The frequencies of both bleeding and organ failure symptoms, and the scores for organ failure or the DIC diagnostic criteria were significantly higher in infectious disease patients with hypofibrinogenemia, suggesting that in patients with infectious diseases, hypofibrinogenemia is associated with more progressive and severe DIC. Although the 28-day survival rate and the DIC resolution rate were both significantly lower for infectious disease patients with DIC with hypofibrinogenemia than for those without hypofibrinogenemia, this difference was not observed in DIC patients with hematological diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hypofibrinogenemia among infectious disease patients with DIC may reflect increased consumption of fibrinogen due to accelerated coagulation reactions, while hypofibrinogenemia among hematological disease patients with DIC may be caused by fibrinogenolysis due to hyperfibrinolysis, and frequently results in bleeding and multiple-organ failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-021-00264-z","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T09:09:41Z","timestamp":1614244181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa"],"prefix":"10.1186","volume":"19","author":[{"given":"Kazuo","family":"Kawasugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9021-8633","authenticated-orcid":false,"given":"Hideo","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goichi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Madoiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"264_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1056\/NEJM199908193410807","volume":"341","author":"M Levi","year":"1999","unstructured":"Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586\u201392.","journal-title":"N Engl J Med"},{"key":"264_CR2","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","volume":"2","author":"S Gando","year":"2016","unstructured":"Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037.","journal-title":"Nat Rev Dis Primers"},{"key":"264_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cca.2014.04.020","volume":"436C","author":"H Wada","year":"2014","unstructured":"Wada H, Matsumoto T, Yamashita Y, Hatada T. Disseminated intravascular coagulation: testing and diagnosis. Clin Chim Acta. 2014;436C:130\u20134.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"264_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1055\/s-0037-1616068","volume":"86","author":"FB Taylor Jr","year":"2001","unstructured":"Taylor FB Jr, Toh CH, Hoots K, Wada H, Levi M. Towards a definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327\u201330.","journal-title":"Thromb Haemost"},{"key":"264_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/2052-0492-2-15","volume":"2","author":"H Wada","year":"2014","unstructured":"Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2:15.","journal-title":"J Intensive Care"},{"key":"264_CR6","first-page":"265","volume":"49","author":"N Kobayashi","year":"1983","unstructured":"Kobayashi N, Maegawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan. Bibl Haemotol. 1983;49:265\u201375.","journal-title":"Bibl Haemotol"},{"key":"264_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/01.CCM.0000202209.42491.38","volume":"34","author":"S Gando","year":"2006","unstructured":"Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625\u201331.","journal-title":"Crit Care Med"},{"key":"264_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12959-016-0117-x","volume":"14","author":"H Asakura","year":"2016","unstructured":"Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. DIC subcommittee of the Japanese society on thrombosis and hemostasis. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42.","journal-title":"Thromb J"},{"key":"264_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12959-017-0142-4","volume":"15","author":"H Wada","year":"2017","unstructured":"Wada H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. DIC subcommittee of the Japanese society on thrombosis and hemostasis. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017;15:17.","journal-title":"Thromb J"},{"key":"264_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","volume":"145","author":"M Levi","year":"2009","unstructured":"Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24\u201333.","journal-title":"Br J Haematol"},{"key":"264_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.thromres.2009.08.017","volume":"125","author":"H Wada","year":"2010","unstructured":"Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Japanese Society of Thrombosis Hemostasis\/DIC subcommittee. Japanese Society of Thrombosis Hemostasis\/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125:6\u201311.","journal-title":"Thromb Res"},{"key":"264_CR12","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.thromres.2011.08.028","volume":"129","author":"M Di Nisio","year":"2012","unstructured":"Di Nisio M, Baudo F, Cosmi B, D'Angelo A, De Gasperi A, Malato A, et al. on behalf of the Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012;129:e177\u201384.","journal-title":"Thromb Res"},{"key":"264_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/jth.12155","volume":"11","author":"H Wada","year":"2013","unstructured":"Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al. The scientific standardization committee on DIC of the international society on thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761\u20137.","journal-title":"J Thromb Haemost"},{"key":"264_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.thromres.2014.07.033","volume":"134","author":"H Wada","year":"2014","unstructured":"Wada H, Okamoto K, Iba T, Kushimoto S, Kawasugi K, Gando S, et al. Japanese Society of Thrombosis Hemostasis\/DIC subcommittee. Addition of recommendations for the use of recombinant human thrombomodulin to the \u201cExpert consensus for the treatment of disseminated intravascular coagulation in Japan\u201d. Thromb Res. 2014;134:924\u20135.","journal-title":"Thromb Res"},{"key":"264_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31\u201341.","journal-title":"J Thromb Haemost"},{"key":"264_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.thromres.2013.03.008","volume":"131","author":"J Mimuro","year":"2013","unstructured":"Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013;131:436\u201343.","journal-title":"Thromb Res"},{"key":"264_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.thromres.2013.12.033","volume":"133","author":"H Asakura","year":"2014","unstructured":"Asakura H, Takahashi H, Tsuji H, Matsushita T, Ninomiya H, Honda G, et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy. Thromb Res. 2014;133:364\u201370.","journal-title":"Thromb Res"},{"key":"264_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2052-0492-2-30","volume":"2","author":"Y Eguchi","year":"2014","unstructured":"Eguchi Y, Gando S, Ishikura H, Saitoh D, Mimuro J, Takahashi H, et al. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care. 2014;2:30.","journal-title":"J Intensive Care"},{"key":"264_CR19","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","volume":"286","author":"BL Warren","year":"2001","unstructured":"Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869\u201378.","journal-title":"JAMA."},{"key":"264_CR20","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","volume":"366","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. PROWESS-SHOCK study group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055\u201364.","journal-title":"N Engl J Med"},{"key":"264_CR21","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2019.5358","volume":"321","author":"JL Vincent","year":"2019","unstructured":"Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. SCARLET Trial Group. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321:1993\u20132002.","journal-title":"JAMA"},{"key":"264_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the working group on Sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"264_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12941-018-0282-9","volume":"17","author":"S Okuzono","year":"2018","unstructured":"Okuzono S, Ishimura M, Kanno S, Sonoda M, Kaku N, Motomura Y, et al. Streptococcus pyogenes-purpura fulminans as an invasive form of group a streptococcal infection. Ann Clin Microbiol Antimicrob. 2018;17:31.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"264_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/1076029616648405","volume":"23","author":"T Iba","year":"2017","unstructured":"Iba T, Gando S, Saitoh D, Ikeda T, Anan H, Oda S, et al. Efficacy and bleeding risk of antithrombin supplementation in patients with septic disseminated intravascular coagulation: a third survey. Clin Appl Thromb Hemost. 2017;23:422\u20138.","journal-title":"Clin Appl Thromb Hemost"},{"key":"264_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0049-3848(83)90223-2","volume":"30","author":"H Wada","year":"1982","unstructured":"Wada H, Nagano T, Tomeoku M, Kuto M, Karitani Y, Deguchi K, et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res. 1982;30:315\u201322.","journal-title":"Thromb Res"},{"key":"264_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.2830420205","volume":"42","author":"H Wada","year":"1993","unstructured":"Wada H, Kumeda Y, Ogasawara Z, Ohiwa M, Kaneko T, Tamaki S, et al. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol. 1993;42:166\u201370.","journal-title":"Am J Hematol"},{"key":"264_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cccn.2004.02.015","volume":"344","author":"H Wada","year":"2004","unstructured":"Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004;344:13\u201321.","journal-title":"Clin Chim Acta"},{"key":"264_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13054-019-2552-0","volume":"23","author":"T Ito","year":"2019","unstructured":"Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23:280.","journal-title":"Crit Care"},{"key":"264_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajh.10249","volume":"72","author":"H Wada","year":"2003","unstructured":"Wada H, Mori Y, Sakakura M, Gabazza EC, Kushiya F, Watanabe M, et al. High plasma levels of fibrinogen are associated with poor outcome. Am J Hematol. 2003;72:1\u20137.","journal-title":"Am J Hematol"},{"key":"264_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/107602960100700309","volume":"7","author":"R Watanabe","year":"2001","unstructured":"Watanabe R, Wada H, Miura Y, Murata Y, Watanabe Y, Sakakura M, et al. Plasma levels of total plasminogen activator inhibitor-I and tissue plasminogen activator\/inhibitor complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Haemost. 2001;7:229\u201333.","journal-title":"Clin Appl Thromb Haemost"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12959-021-00264-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T09:31:35Z","timestamp":1614245495000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-021-00264-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1186\/s12959-021-00264-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-86887\/v1","asserted-by":"object"}]},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"1 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval for this study was obtained from the appropriate ethics committees and institutional review boards of Mie Prefectural General Medical Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Asahi Kasei Pharma Corporation absorbed expenses for the analysis and the English language editing of manuscript. N.K. received no grants or personal fees. H.W. received grants and personal fees from Asahi Kasei Pharma Corporation and Japan Blood Products Organization outside the present work. T.U., S.M., N.T., K.S., Y.S., and K.O. received personal fees from Asahi Kasei Pharma Corporation outside the present work. K.K. and T.I<sup>j<\/sup>. received grants and personal fees from Asahi Kasei Pharma Corporation outside the present work. G.H. is an employee of Asahi Kasei Pharma Corporation. T.I<sup>k<\/sup>. received research grants from Japan Blood Products Organization and Japan Immunoresearch Laboratories outside the present work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}